GALT
Galectin Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.61
+5.98%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.05
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.09
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -21.8%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026